Product Information
| Property | Description |
|---|---|
| Product Name | Anti-human CCR10 Recombinant Monoclonal Antibody |
| Antibody ID | HM0074 |
| Target Protein | C-C chemokine receptor type 10 |
| Target Protein Short Name | CCR10 |
| UniProt Accession | Human: P46092 |
| Molecular Weight | Human: 38.4 kDa |
| Antibody Type | Recombinant monoclonal antibody |
| Host Species | Mouse |
| Recombinant Format | Full-length mouse IgG1 |
| Isotype | Mouse IgG1 |
| Species Reactivity | Human |
| Tested Applications | WB |
| Recommended Dilution for WB | 1:500–1:5000 |
| Antigen | Recombinant epitope-Fc fusion protein |
| Epitope Sequence | TEATEQVSWGHYSGDEEDAYSA |
| Expression System | HEK293 cells |
| Purification | Protein G affinity chromatography |
| Conjugate | Unconjugated |
| Concentration | 0.1 mg/mL |
| Storage Buffer | 0.1 M Tris, 0.05 M Glycine, 0.07 M NaCl, 2 g/L BSA, 50% glycerol, pH 7 |
| Storage Condition | Store at -20°C. |
| Research Use | For research use only. Not for diagnostic or therapeutic applications. |
Product Background
CCR10 (C-C chemokine receptor type 10) is a chemokine receptor involved in immune cell trafficking, skin-associated immune responses, mucosal immunity, and inflammatory signaling pathways. CCR10 is expressed in subsets of lymphocytes and epithelial-associated immune cells and plays important roles in chemokine-mediated migration.
CCR10 is widely studied in immunology, inflammation, mucosal biology, skin biology, cancer immunology, GPCR signaling, and immune cell trafficking.
Antibody Development
HM0074 was generated by phage-display selection using a mouse-derived antibody library. Recombinant epitope-Fc fusion protein containing the hCCR10 epitope sequence was used as the selection antigen. Following identification of the initial antibody candidate, structure-guided affinity optimization was performed to improve binding affinity and specificity.
The optimized antibody was reconstructed as a full-length mouse IgG1 recombinant antibody and expressed in HEK293 cells.
Binding and specificity were evaluated by:
- ELISA using recombinant epitope-Fc fusion antigen
- Western blot using recombinant MBP-epitope fusion protein
- Western blot detection of endogenous full-length hCCR10 protein
Validation Data
ELISA Validation
ELISA demonstrated specific binding to recombinant epitope-Fc fusion antigen, while minimal binding was observed against Fc control protein.
Validation conditions:
- Well 1: Fc control protein
- Well 2: Epitope-Fc fusion protein
- Detection substrate: TMB
Note:
ELISA validation confirms binding to the epitope-Fc fusion antigen. Full-length CCR10 protein binding in solution has not been tested by ELISA.
Western Blot Validation – Recombinant Fusion Protein
Western blot analysis demonstrated specific recognition of recombinant MBP-epitope fusion protein expressed in BL21(DE3) cells, while minimal binding was observed against MBP control protein.
Validation conditions:
- Lane 1: MBP control protein
- Lane 2: MBP-epitope fusion protein
- Standard reducing Western blot
Western Blot Validation – Endogenous Full-Length Protein
Western blot analysis detected endogenous full-length CCR10 protein under reducing conditions.
Validated samples:
- HeLa cells
- HepG2 cells
Detection condition:
- Standard reducing Western blot
- HRP-conjugated anti-mouse secondary antibody
Observed bands:
- Major bands observed near expected molecular weight for endogenous hCCR10 protein
Additional lower molecular weight bands may represent processed receptor forms, degradation products, or alternative receptor-associated species commonly observed for GPCR targets under reducing Western blot conditions.















